Group 1 - Company Tianjin Development (00882.HK) announced its indirect subsidiary, Lisheng Pharmaceutical (002393.SZ), plans to establish a fund with several partners, with a proposed total subscription amount of RMB 500 million [1] - Lisheng Pharmaceutical intends to contribute RMB 173.75 million, representing 34.75% of the total proposed subscription amount for the fund [1] - The fund, tentatively named Jian Sheng Guo Xin Tai Da Equity Fund Partnership (Limited Partnership), aims to invest in the health and biotechnology sectors in China [1] Group 2 - The board believes that the potential transaction will enhance the group's understanding of the latest developments in the pharmaceutical industry, diversify investment risks, and identify potential strategic partners for future opportunities [2] - The group's investment in the fund is expected to provide more industry acquisition opportunities aligned with its development strategy and offer potential returns exceeding fixed income, thereby improving capital allocation efficiency and returns [2]